https://www.pharmaceutical-technology.com/news/blueprint-medicines-ayvakit-approval/
Blueprint Medicines has secured US FDA approval for Ayvakit for treating unresectable or metastatic gastrointestinal stromal tumour among adults (GIST).
fda approvalblueprintmedicinessecuresayvakit